A Phase 2 interventional study of AXS-05 and Placebo in Treatment Resistant Depression and Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-12.
Sponsored by Axsome Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 87th largest by enrollment of the 181 interventional ones that give a count, is one of 15 that started in 2020, is one of 52 in phase 2, and was the 113th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 83 across the 22 observational. Of the 119 that completed or were terminated, 70 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 204 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD).
This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.
Key Eligibility Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AXS-05
Drug: Placebo
AXS-05 taken daily for up to 52 weeks, until relapse.
Placebo taken daily for up to 52 weeks, until relapse.
Relapse
Assessed by clinician-rated scales.
Time frame: Time from randomization to first relapse (up to 52 weeks)
Plan to share: No
Ran from Aug 2020 to primary completion in Jul 2021, 11 months.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05
Depressive Disorder, Treatment-Resistant →